drugset / Trial / NCT00105287

Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

NCT00105287

Phase 3 Completed 100 enrolled Cephalon
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.

Timeline

Start
2005-01
Primary completion
2006-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified

Indications